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Introduction: Radiotherapy treatment for prostate
cancer can cause bowel problems, which may lead to
severe difficulties for cancer survivors including
limiting travel, work or socialising. These symptoms
can appear at any time following radiotherapy.
This study focuses on the early identification and
protocol-based management of effects known to cause
long-term, or even permanent, changes to the
well-being of prostate cancer survivors. The rationale
of this study is to improve the care offered to men
and their families following pelvic radiotherapy for
prostate cancer.
Method and analysis: Implementation research
methodology will be used to adopt a multicomponent
intervention at three UK centres. The intervention
package comprises a standardised clinical assessment
of relevant symptoms in oncology outpatient clinics
and rapid referral to an enhanced gastroenterological
service for patients identified with bowel problems.
Gastroenterology staff will be trained to use an expert-
practice algorithm of targeted gastroenterology
investigations and treatments. The evaluation of the
intervention and its embedding within local practices
will be conducted using a mixed-methods design. The
effect of the new service will be measured in terms of
the following outcomes: acceptability to staff and
patients; quality of life; symptom control and cost-
effectiveness. Data collection will take place at baseline,
6 months (±2 months), and 12 months (±2 months)
after entry into the study.
Ethics and dissemination: The study has ethical
approval from the North West-Liverpool East Research
Ethics Committee and the appropriate NHS governance
clearance. All participants provide written informed
consent. The study team aim to publish the results of
the study in peer-reviewed journals as well as at
national and international conferences.
Trial registration number: UKCRN16974
INTRODUCTION
Prostate cancer is the most common cancer
in men in the UK except for non-
melanomatous skin cancer. Indeed, 47 300
men were diagnosed in the UK with prostate
cancer in 2013.1 Men with organ-conﬁned
localised disease have extremely good short-
term prostate cancer survival rates with over
95% alive at 5 years after diagnosis and 84%
at 10 years.1 2 There are several radical treat-
ment options available for prostate cancer.
Much evidence exists relating to the short-
term and long-term effects of the major
established therapies (prostatectomy, exter-
nal beam radiotherapy and low-dose rate
brachytherapy).3 Despite these side effects of
treatment, many men remain satisﬁed with
their treatment and they would select the
same treatment again.4
Late effects of pelvic radiotherapy
Radiotherapy is important in the treatment
of cancers.5 It is estimated conservatively that
Strengths and limitations of this study
▪ The study uses mixed methods, using both
qualitative and quantitative approaches to data
collection and analysis enabling solutions to any
problems that arise can be made in real time.
▪ The study is restricted to the recruitment of
patients with prostate cancer with late gastro-
intestinal effects of pelvic radiotherapy, thereby
reducing the sample size and generalisability to
other cancer diagnoses and treatment modalities.
In addition, the implementation of the interven-
tion may not be successful.
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17 000 patients with cancer receive pelvic radiotherapy
per year in the UK.6 Of these an estimated 90% develop
a permanent change in their bowel habit and 50%
experience a reduction in their quality of life, and 20–
40% rate the effect on quality of life as moderate or
severe.7 In a more recent study 35% of prostate patients
with cancer suffered from bowel urgency 15 years after
radiotherapy.8
Despite the signiﬁcant impact of these symptoms on
quality of life, only one in ﬁve patients who develop
gastrointestinal (GI) symptoms after pelvic radiotherapy
are referred to a gastroenterologist.9 There are several
reasons for this low referral rate. First, patients may not
offer up their symptoms to the treating doctor, despite
the potentially catastrophic effects to their physical, emo-
tional and social well-being. Explanations for this behav-
iour include reasons such as: patients may view them as
expected consequences of therapy; they may be too
embarrassed to mention them; or, they might just be
grateful for being cured.10 Second, clinicians looking
after patients might not seek information on late radi-
ation effects, focusing primarily on symptoms of cancer,
partly as late effects have been considered to be
irreversible.11
Current patterns of care
The long-term care of men with curable or cured pros-
tate cancer varies between countries. There are also
intracountry variations, particularly in the UK where
healthcare has been devolved.12 Variations in managing
late GI effects of pelvic radiotherapy across the UK have
been highlighted by two recent surveys of patterns of
care aimed at clinical oncologists and gastroenterolo-
gists.6 13 The oncologist survey reported that 91 of 190
(48%) responding clinicians refer <10% of patients for
specialist evaluation.6 The majority of responding oncol-
ogists (58%) did not have a local or regional gastro-
enterological or colorectal surgical colleague with a
special interest in postradiation bowel dysfunction and
52% of these oncologists felt their current service was
inadequate.6 The results from the gastroenterologist
survey were broadly similar. Most gastroenterologists
(59%) thought the service should be managed by a
gastroenterologist with a special interest. However, most
gastroenterologists (81%) lacked a specialist interest,
with only 48% rating their current service as adequate.13
Managing late GI effects of pelvic radiotherapy
Research carried out by the Gastro Intestinal and
Nutrition Team (GIANT) service at The Royal Marsden
National Health Service (NHS) Foundation Trust identi-
ﬁed over 20 symptoms that occur frequently after pros-
tate radiotherapy.14 Of the patients experiencing GI
symptoms one-third will have a diagnosis unrelated to
their radiotherapy.7 As the underlying diagnosis, symp-
toms and pathophysiology varies between patients,
empirical therapies are unlikely to be successful.10
The Optimising Radiotherapy Bowel Injury Therapy
(ORBIT) trial,9 demonstrated that these symptoms can
be diagnosed accurately and that they can be treated
effectively at very modest cost compared to the cost of
the cancer treatment itself, and that this approach leads
to improvements in pelvic radiation-induced GI symp-
toms as measured by Inﬂammatory Bowel Disease
Questionnaire- Bowel (IBDQ-B) scores. The ORBIT trial
showed that patients who were offered targeted interven-
tions from clinicians who followed a detailed algorithm
had better improvements in GI symptoms when com-
pared to patients who were given usual care.9 This evi-
dence also demonstrated that for most patients a
specially trained nurse could deliver this assessment and
treatment just as effectively as a consultant.
Research required
The Royal Marsden Hospital (RMH) is currently the
only centre of excellence in the UK for managing late
effects using the algorithm from the ORBIT trial.9 An
implementation study is thus required to establish a new
service to help manage the late GI effects that develop
after pelvic radiotherapy. In order for a new service to
manage patients with late GI effects of pelvic radiother-
apy successfully, engagement and enthusiasm from both
local oncology and gastroenterology services is highly
important. Long-term sustainability (ie, the ability to
move from short-term research funding into long-term




The aim of this study is to implement successfully an
innovative service that aims to improve the care offered
to men diagnosed with prostate cancer, and also to their
partners and families, in a postcurative treatment setting
at three sites.
The speciﬁc objectives are:
▸ To raise awareness and increase expert capacity for
the treatment of GI late effects following
radiotherapy;
▸ To implement a tested interventional model of care
in order to develop centres of excellence that are
speciﬁcally focused on the early identiﬁcation and
management of GI late effects;
▸ To evaluate the effectiveness of the new service via
healthcare usage analysis, health economics, quality
of life and by assessing the acceptability to healthcare
professionals (HCP) and patients and families;
▸ To monitor the experiences of patients, support
givers and members of staff regarding service imple-
mentation. The speciﬁc objectives here are:
– To investigate the barriers to setting up a new
service in local practice;
– To evaluate solutions to those barriers;
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– To assess the effectiveness of training in relation to
safe and independent coordination of services.
The intervention
The proposed intervention (outlined in ﬁgure 1) is a
package of multidisciplinary care aimed at the early
identiﬁcation and the subsequent intervention to reduce
the physical, psychological and social impact of late GI
effects after curative treatment for prostate cancer.
Study design
The Evaluating and Addressing the Gastrointestinal Late
Effects (EAGLE) study is a mixed methods implementa-
tion study. The study involves the development of a new
package of enhanced assessment, multidisciplinary care
and use of treatment algorithms will be assessed within
an implementation-research framework. Implementation
research can be deﬁned as ‘the scientiﬁc inquiry into
questions concerning implementation—the act of carry-
ing an intention into effect, which in health research
can be policies, programmes or individual practices (col-
lectively called interventions)’.15 The success of the
implementation is based on real-world outcomes; accept-
ability; adoption; appropriateness; feasibility; ﬁdelity;
implementation cost; incremental cost of intervention
delivery and costs to other NHS services; coverage;
sustainability.16
Outcomes will be measured via collection and analysis
of both quantitative and qualitative data sets. Mixed
methods are suitable for implementation research as
they provide a practical way to understand multiple per-
spectives and outcomes.15 This approach will involve a
quantitative before and after (treatment) study, as well as
a substudy involving the use of a comparison group and
a qualitative study.
This study will use an overarching framework suited to
complex interventions called normalisation process
theory (NPT).17 NPT is a pragmatic theory that exam-
ines the factors needed for successful implementation
into local practice. NPT allows one to examine those
factors that are essential for new initiatives in healthcare
settings where multiple stakeholders’ perspectives and
resource availability can ‘sink’ new developments or can
undermine trials.18 Murray et al18 and Meyer et al19 dis-
cussed the role of NPT in testing the feasibility, adher-
ence and acceptance of initiatives. These analyses were
coupled with an evaluation of cost and sustainability per
site, albeit with scope for local idiosyncrasies.
Implementation centres
This study will be carried out in three centres across the
UK. Sites will be invited to complete a template of exist-
ing services to apply for selection to the study (see
online supplementary ﬁle 1 for an example of the site
information form).
Criteria for site selection:
▸ Clinical oncology team (from the same catchment
area as the gastroenterology team) managing around
100 patients per year with prostate cancer who have
been treated with radical radiotherapy.
▸ Ability to identify a prostate-cancer oncologist willing
to use the Assessment of Late Effects of
RadioTherapy-Bowel (ALERT-B) screening tool to
identify and recruit patients for the EAGLE study.
▸ Ability to identify a gastroenterologist who is willing
to:
– Support the introduction of a non-consultant post
following the ‘Guide to Managing Gastrointestinal
Symptoms of Pelvic Radiation Disease for investiga-
tion and management of pelvic radiation disease’;20
– Provide ongoing clinical support to the non-
consultant postholder;
– Adhere to the RMH algorithm;
– Lead the local process for securing sustainable
funding.
▸ Additional key considerations include ongoing local
developments in this ﬁeld including involvement of
oncologists managing patients with other cancers
who are known to suffer pelvic radiation disease
(PRD).
Enhanced staff training
Training options for the specialist PRD team will include
completion of the Macmillan Cancer Support-RMH
online training module, teaching and support sessions
with the RMH nurse consultant, and visits to the RMH
PRD multidisciplinary clinic to gain experience of how
Figure 1 Summary of the intervention. The figure offers a
breakdown of the gastrointestinal intervention provided as part
of the study. Patients will be screened for late gastrointestinal
effects in oncology using a simple screening tool,
ALERT-B. Patients with symptoms will then be referred to
gastroenterology to a specialist team who will follow an
algorithm to offer targeted investigations and treatment.
ALERT-B, Assessment of Late Effects of
RadioTherapy-Bowel; EAGLE, Evaluating and Addressing the
Gastrointestinal Late Effects study; GI, gastrointestinal.
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the PRD service is delivered at the RMH. The GI and
nutrition team at the RMH have developed a robust
teaching package and supportive documentation for
new units. This teaching programme is supported by an
online validated BSc/MSc module run by The Royal
Marsden School. This training package will be aimed at
both the specialist PRD team and the wider non-
specialist oncological and gastroenterological teams.
Once a service is established, intermittent multidisciplin-
ary update sessions (at least annually) will be provided
to ensure that skills are maintained. These update ses-
sions will be provided within EAGLE by ongoing support
from the RMH PRD multidisciplinary team (MDT) for
the duration of the study.
Enhanced MDT care
A streamlined referral pathway to a named healthcare
professionals in the new multidisciplinary PRD service in
each centre will be established for EAGLE study partici-
pants who are identiﬁed with late GI effects of pelvic
radiotherapy. The referral will include relevant oncology
and radiotherapy treatment information. During the
ﬁrst appointment at the new gastroenterology clinic, a
comprehensive medical history will be taken. Detailed
gastroenterological status will be ascertained by following
the RMH algorithm, which will be used to arrange
appropriate investigations.9 A list of investigations can be
found in online supplementary ﬁle 2.
Follow-up investigations will be arranged by telephone
or clinic visits as necessary, although it is envisaged that
patients will be seen in clinic at a minimum of 6 and
12 months after initial assessment. Stafﬁng, coordination
and running of enhanced services will be agreed on a
site-by-site basis, according to local preferences. The
research team will liaise with these sites to create proto-
cols for practice that are agreed locally, as required.
Participant selection and recruitment
Establishing patient eligibility will be a two-stage process.
Initially, those patients attending urology/oncology
follow-up clinics that received radiotherapy treatment
for prostate cancer at least 6 months previously will be
asked to consent to the registration phase of EAGLE by
a Good Clinical Practice (GCP) trained healthcare pro-
fessional working at the oncology clinic.
Those patients who consent will be screened for eligi-
bility by completing the ALERT-B tool. The ALERT-B
tool (see online supplementary ﬁle 3) has been devel-
oped and tested for content and face validity,21 by
members of the EAGLE research team previously as part
of a Tenovus Innovation Grant. As part of the EAGLE
study, the ALERT-B tool will also be validated in terms of
reliability against the Gastrointestinal Symptom Rating
Score (GSRS).
The ALERT-B tool will be reviewed with the patient by
the clinical nurse specialist (CNS), research nurse,
research radiographer or doctor. Those patients with at
least one ‘yes’ response to one of the three questions
(experiencing faecal incontinence, rectal bleeding or
signiﬁcant impact on quality of life) will be identiﬁed to
the consultant oncologist and they will be registered for
the EAGLE study. Patients will be offered the choice to
be referred to the multidisciplinary pelvic disease clinic
and they will be given written information about the
EAGLE study.
At both stages, patients will be excluded if they meet
one or more of the following criteria: any factor that
affects their ability to communicate their wishes; an
inability to comprehend what is being asked of them; a
lack of capacity to consent; or, cancer recurrence.
To beneﬁt the maximum number of men, patients will
be recruited until the local gastroenterology service cap-
acity is reached. It is estimated that 100 patients from
each centre will be screened annually and those patients
who are referred will be managed within the service for
12 months with an average of three appointments during
this time. Long-term, the expectation is that a full-time
CNS would manage ∼150 new patients per year.
Participants for interviews
Participants will be sampled purposively from the three
research sites across three groups to represent:
1. Oncology and GI HCPs in order to capture staff atti-
tudes to implementation;
2. Patients receiving services in order to capture patient
experience of services;
3. Support givers to the family in order to represent
family or caregiver perspectives of services.
The study aims to recruit 10–15 participants from
each of the three groups listed above. Participants will
be interviewed at three time points over the course of 8–
14 months. Interviews will also be conducted with key
informants on a local basis, where appropriate. For
example, these informants include primary care provi-
ders and other stakeholders including Macmillan
Cancer Support services, commissioners and Local
Health Board representatives.
Participants must be aged 18 years and over and they
must be able to undertake an interview in English
without the need for translation (unless local translation
services are readily available) in order to be eligible for
inclusion in the study. All those participants who are eli-
gible will be asked to participate until enough partici-
pants have been recruited to represent each group (ie,
until ‘saturation’) and to allow for follow-up interviews.
Participants will be interviewed by either a face-to-face
interview at a location of their choice or over the tele-
phone. Interviews will last ∼30–60 min. The interview will
be terminated earlier if a participant is thought to be fati-
gued, upset or becomes unwell. In the event of partici-
pant distress due to discussion of sensitive topics, or if a
clinical or work-related issue emerges, the researchers,
will react at the time according to their own experience.
The researchers will then refer the issue to the partici-
pant’s clinical team (with the participant’s permission).
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Data collection
Data will be collected at baseline, 6 months (±2 months)
and 12 months (±2 months) after entry into the study by
a member of the research team. The diagram below
(ﬁgure 2) demonstrates the pathway that EAGLE partici-
pants will follow and the data collection instruments that
will be used in the study. A case report form for each
assessment point will be assigned to each participant in
order to collect questionnaire and relevant clinical data.
There are multiple (end point) domains to be consid-
ered including: physical; psychological; sexual; ﬁnancial;
and, social domains. There is some level of interdepend-
ence and overlap between these domains. The study will
focus initially on physical effects, which can be broadly
separated into gastrointestinal, genitourinary, sexual,
endocrinal and fatigue. The study end points are
designed to capture acceptability and effectiveness of
the intervention and are as follows:
▸ Bowel-speciﬁc health-related quality of life (HRQoL);
▸ Global HRQoL;
▸ Prostate-speciﬁc HRQoL;
▸ Patient, support giver and staff experience;
▸ Healthcare resource usage;
▸ Cost and acceptability of staff training.
Bowel-specific HRQoL
The GSRS is a validated questionnaire addressing symp-
toms that are important and relevant to patients with
general GI symptoms. GSRS evaluates the absence or
presence (and severity) of 15 GI symptoms using a four-
point response scale over a 1-week period prior to
administration. GSRS assesses ﬁve domains that have
been identiﬁed as important to GI integrity: reﬂux syn-
drome; acute pain syndrome; indigestion syndrome;
diarrhoea syndrome; and, constipation syndrome. GSRS
has a range of scores going from zero to three (zero
representing good health and three poor health). This
questionnaire was chosen for use in this study because
its reliability and validity are well-documented and
normal values for a general population are available.22
Global HRQoL
Global HRQoL will be measured using the EQ-5D-5L
and the European Organisation for Research and
Treatment of Cancer Quality of Life Core Questionnaire
30 (EORTC QLQ C30).
A newly released validated version of the EQ-5D-5L
with ﬁve response categories (mobility, self-care, usual
activities, pain/discomfort and anxiety/depression) for
each dimension provides enhanced discriminatory
power will be used in the study.23 This tool also measures
HRQoL using a vertical visual analogue scale.24
The 30-item questionnaire incorporates ﬁve functional
scales and is a reliable and clinically valid measure of
quality of life in patients with cancer.25 Participants will
be asked to complete a number of questionnaires, and so
to limit the burden of this process they will be required to
answer only questions 29 and 30 (ie, items that rate
overall global health and quality of life) from the EORTC
QLQ C30 questionnaire. Item responses to these two
questions from the EORTC QLQ C30 questionnaire are
numerical scales going from 1 to 7. The scores from both
items are added together and their sum is transformed
linearly to lie in the range 0–100, where 0 represents the
worst possible global HRQoL and 100 represents the best
possible global HRQoL.
Prostate-specific HRQoL
Prostate-speciﬁc HRQoL will be measured using the
European Organisation for Research and Treatment of
Cancer Quality of Life Questionnaire Prostate Cancer
module (EORTC QLQ-PR25) and the Expanded
Prostate Cancer Index Composite (EPIC-26). Both pros-
tate questionnaires were requested by the funder,
Prostate Cancer UK (PCUK), to collect data as part of a
series of global projects.
The EORTC QLQ-PR25 questionnaire contains 25
items that are grouped into 5 multi-item scales. High
scores reﬂect either more symptoms (urinary, bowel,
hormonal treatment-related symptoms) or high levels of
functioning (sexual).26 All items and scale scores of the
EORTC QLQ-PR25 are transferred linearly onto a 0–100
scale, with higher scores again reﬂecting either more
symptoms (urinary, bowel, hormonal treatment-related
symptoms) or higher levels of functioning (sexual).24 A
shorter 26-item version of EPIC was designed and vali-
dated.27 EPIC-26 has shown satisfactory test–retest reli-
ability and internal consistency for the urinary, bowel,
sexual and hormonal domains.28
Acceptability
Experience of the new service will be explored via longi-
tudinal semistructured interviews with participants. The
data obtained from these interviews will be used to high-
light problems or to inform necessary adjustments of GI
symptom screening and the new gastroenterology
service. In addition interviews with participants and
support givers will provide an insight into the psycho-
logical and social impact of GI symptoms and the new
GI service. At the time of completion of the study, an
analysis will be carried out of all of the data sets in order
to report common themes and differences across partici-
pant groups and settings. This analysis will contribute to
a model of implementation for future sites in the UK.
Health resource usage
Resources used to deliver the intervention in all of the
centres will be monitored prospectively, including those
resources used in training staff, screening patients and
all patient contact, investigations, etc. Research costs
will be isolated and they will not be included in the
costing.
Resource usage data will be collected via two bespoke
resource-use questionnaires. One questionnaire will be
completed by all participants and the other question-
naire will be completed by designated health
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professionals. Both questionnaires will be administered
at baseline and at each follow-up point. Patient recall
has been shown to be a valid method for collecting NHS
resource-use data.29
Comparative patient data
Comparative patient subsequent resource use data will
be collected from a Cardiff subgroup. Participants in the
substudy will be managed following current standard
care, either within the Velindre Cancer Centre or with
referral to gastroenterology services in Cwm Taf. Data
from this group will help to compare the impact of the
new GI service against standard care. These patients will
be given information on the substudy, which will involve
an assessment of their healthcare resource usage and
health-related quality of life over a 12-month period
from study entry. The EQ-5D-5L and EPIC-26 will also
be completed at each data collection point.
Figure 2 EAGLE study Pathway. The figure provides an overview of the study processes and data collection at different stages
of the EAGLE study. Participants will consent to be screened for the late gastrointestinal effects of radiotherapy at their routine
oncology appointments. Only patients identified with bowel symptoms will be offered a referral to gastroenterology where consent
will be taken for questionnaire data collection at three time points (baseline, around 4–8 months and 10–14 months). ALRT-B,
Assessment of Late Effects of RadioTherapy-Bowel; CNS, clinical nurse specialist; EAGLE, Evaluating and Addressing the
Gastrointestinal Late Effects study; HRQoL, health-related quality of life; GSRS, Gastrointestinal Symptom Rating Score.
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Data analysis
Participant and treatment characteristics will be
explored by using descriptive statistics. Measures of
centre (mean and median) and measures of spread (SD
and IQR) will be used to characterise outcome mea-
sures. Subscale, and any appropriate overall scores, will
be found according to relevant scoring manuals (eg, for
EORTC QLQ-C3030 or EPIC31) and with the use of any
pre-existing and tested software (eg, in R using the pre-
existing package ‘QoLR’ for EORTC QLQC30 and
PR25). Improvement in outcomes will be reported by
comparing the 6 and 12-month follow-up measures to
the baseline measurements and to the shadow compari-
son group. Effect sizes such as standardised means from
pretreatment to post-treatment (for 6 months post via,
eg, (mean baseline—mean 6 post)/SD baseline) will be
used to characterise these improvements. Standard
methods for comparing paired or repeated-measures
data will be employed in order to test if improvements
are statistically signiﬁcant at the 5% level (eg, paired
tests and repeated-measures analysis on variance using
parametric or non-parametric methods, as appropriate).
All participants will be encouraged to complete all of
the questionnaires at all of the time points, and so it is
imagined that complete-case analysis can be employed.
A generic procedure will be used for missing data that
forms subscale scores from those items (appropriately
weighted) in a subscale that are non-missing, if no more
than 50% of items in the subscale are missing. If more
than 50% of items are missing then the subscale score is
also set to be missing. This process accounts for ‘item-
wise’ missing data when forming subscale scores for
each patient, although it does not account for any attri-
tion of patients during the study. If attrition from the
study does occur (eg, through cancer recurrence
through the course of the intervention, unacceptability
of the intervention to some men, or burden of the
research) then appropriate statistical modelling techni-
ques that account for this effect and/or the use of
imputation techniques (eg, multiple imputation) can be
employed.
Cost-effectiveness analysis
A cost-effectiveness analysis in the form of a cost utility
analysis, comparing participants in the EAGLE study
with those not receiving the service will be undertaken
from an NHS perspective for the primary analysis. Total
costs (intervention plus or minus any subsequent differ-
ences in NHS costs) will be assessed against effects in
terms of quality adjusted life years (QALY) based on the
EQ-5D-5L. The estimated incremental cost per QALY
from the service can be compared with the willingness
to pay threshold of £20 000–£30 000 per extra QALY cur-
rently used by The National Institute for Health and
Care Excellence (NICE).32
Secondary analysis will take a wider perspective and
will include missed workdays and patient-borne costs
(including out-of-pocket expenses relating to travel,
carer provision and incontinence products). The sensi-
tivity of the conclusions to changes in assumptions will
be assessed via sensitivity analysis.
Costing staff training
Professionals delivering the intervention will be asked to
complete a training record on a weekly basis throughout
the duration of the research study. This record will facili-
tate measurement of training costs, which will feed into
the cost-effectiveness analysis. All formal training, in add-
ition to more ad hoc training and support from dieti-
cians, consultants or other healthcare professionals, will
be logged regardless of whether it is received during or
outside of working hours.
Interview data analysis
The researcher will audio record the interview digitally.
Interviews will be transcribed verbatim and the interview
data will be uploaded to qualitative analysis software
called QSR NVivo V.10. Ten per cent of transcripts will
be co-coded by a senior researcher as a measure of reli-
ability. Each interview will be read initially with a deduct-
ive approach to isolate signiﬁcant problem areas in the
implementation delivery. The anonymised data will be
represented by selected extracts in a narrative format
with a thematic structure.
Data will be analysed in order to identify problems
with local systems and procedures. This analysis will also
explore the HCP and patient and support giver attitudes
and experiences. Framework analysis is the most appro-
priate analytic method to achieve these aims for the
interview data.27 Framework analysis is suited to applied
health research in which a certain amount of existing
knowledge is available and where the aim of the study is
to inform future practice rather than theoretical devel-
opment.33 Framework analysis ‘involves a systematic
process of sifting, charting and sorting the material into
key issues and themes’.27 It allows the integration of a
priori issues into the emerging data analysis and it pro-
vides a clearly deﬁned analytical structure that contri-
butes to the transparency and validity of the results. The
matrix for the framework analysis will be developed
from a deductive approach using NPT, further sup-
ported by an overall inductive analysis of spontaneously
arising themes during interviews.34
Project management
A study management group (SMG) will be responsible
for the day-to-day management of the study and they will
meet regularly to advise on the promotion and running
of the study. SMG members will include the chief investi-
gator (CI), coinvestigators, project staff and patient
representatives. Members will sign a SMG charter outlin-
ing their roles. The study will be coordinated through
the Marie Curie Palliative Care Research Centre.
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Consent
Signed consent will be taken at least 24 hours after the
patient has been given the relevant participant informa-
tion sheet.
A separate information and consent process to the
main study will be used for interviews as this is a subset
of the main study. The principal investigator or clinical
team at each site will identify and discuss the interview
substudy with eligible patients, support givers and HCPs
before consent can be obtained. Similarly, the partici-
pant will remain free to withdraw at any time from the
study. All data will be withdrawn at request.
Confidentiality and data management
The CI and the research team of EAGLE will preserve
the conﬁdentiality of participants in accordance with the
Data Protection Act 1998.35 Data will be stored on a
password-protected computer located in secure
University buildings and appropriately backed up. All




Currently only a small proportion of patients are
referred to a gastroenterologist for further investigation
into bowel symptoms that develop after pelvic radiother-
apy. This may be because patients feel uncomfortable
discussing their bowel symptoms with healthcare profes-
sionals.10 The SMG will draw on their considerable
experience in conducting research in this area to ensure
a design sensitive to this patient group.
Research data and patient-related information will be
managed in accordance with relevant regulatory
approvals. The study has been adopted onto the UK
Clinical Research Network (UKCRN) portfolio under ID
number 16974. In addition the study is sponsored by
Cardiff University (SPON1238-14).
Public and patient involvement
Public and patient involvement has been integral to the
conduct of this study from the initial funding applica-
tion. The SMG includes two research partners who have
personal experience of the effect that late GI effects of
pelvic radiotherapy can have on the patient and their
family and friends. The research partners provide a valu-
able source of experience that has particularly helped
when drafting appropriate participant-facing study docu-
ments. Members of the research team will work along-
side the research partners to identify and address
speciﬁc support or training requirements to enable their
effective participation.
Methods of disseminating the findings
Multiple methods of disseminating the ﬁndings will
include a written report for the study funders, PC UK,
including an executive summary with clearly identiﬁed
practice suggestions to beneﬁt patients, support givers
and HCPs. The study will adhere to PCUK data sharing
agreement with the National Cancer Research Institute
(NCRI). As PCUK is a member of the NCRI, an agree-
ment is in place to share anonymous data on the research
portfolio with the International Cancer Research
Partnership (ICRP). Papers detailing the results of this
study will be submitted for publication in peer-reviewed
journals and at national and international conferences.
Participants (or their families) will be informed on
request about the progress of the study. Summary reports
will be displayed on the website, although patients or
their families will be able to request hard copies if they
prefer. For reasons of conﬁdentiality, original data
(audio recordings) and transcripts will not be shared.
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